CardIQ Suite vs EchoNext

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

CardIQ Suite

by GE Medical Systems SCS

EchoNext

by Pathway Labs

AI Verdict

CardIQ Suite and EchoNext are adjacent tools in cardiology AI, both aiding in heart disease diagnosis but with distinct approaches. CardIQ Suite focuses on post-processing cardiac CT scans for detailed anatomical and plaque analysis, ideal for advanced imaging workflows. EchoNext, conversely, analyzes standard ECGs to screen for hidden structural heart disease, offering a non-invasive and potentially earlier detection method.

Choose CardIQ Suite if…

Choose CardIQ Suite if your practice primarily utilizes cardiac CT imaging and requires an on-premise solution for comprehensive post-processing. This tool excels in automating calcium scoring, detailed CCTA review with cine capability, and precise plaque quantification for in-depth cardiovascular disease diagnosis and treatment planning.

View CardIQ Suite →

Choose EchoNext if…

Choose EchoNext if your focus is on early, non-invasive screening for hidden structural heart disease using standard ECGs, particularly in settings like primary care or community practices. This AI-powered tool is ideal for identifying risks of heart failure, valve disease, and pulmonary hypertension, offering broad accessibility through a clinical decision support platform.

View EchoNext →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	CardIQ Suite	EchoNext
Pricing	Contact for pricing	Starts at $600/month
Deployment	On-premise (GE Advantage Workstation (AW) and AW Server (AWS))	Available through the OpenEvidence clinical decision support platform.
BAA Available	Yes AI-estimated	Yes AI-estimated
FDA Status	1 AI-estimated	Yes AI-estimated
HIPAA	Yes AI-estimated	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Tie

Both tools aim to streamline workflows. CardIQ Suite focuses on an integrated workflow for cardiac CT post-processing, offering automated features and seamless transitions between calcium scoring and CCTA review. EchoNext integrates with the OpenEvidence clinical decision support platform, suggesting ease of access within existing physician workflows. Without direct user experience reviews for either, it's difficult to definitively pick a winner, leading to a tie in this dimension.

Clinical Value

EchoNext

EchoNext demonstrates superior clinical value by detecting a broader range of hidden structural heart diseases from standard ECGs, including heart failure, valve disease, and pulmonary hypertension, with reported higher accuracy than cardiologists. CardIQ Suite primarily focuses on automated calcium scoring and CCTA review for cardiovascular disease diagnosis and treatment planning, which is valuable but more specialized.

Pricing & Value

EchoNext

EchoNext offers transparent tiered pricing starting at $600/month, with details on discounts and add-ons, allowing for clearer budget planning. CardIQ Suite's pricing is listed as 'contact for pricing,' which lacks transparency and makes it difficult to assess its value proposition without direct engagement with the vendor.

Enterprise Readiness

EchoNext

EchoNext is available through the OpenEvidence clinical decision support platform, which is used by 650,000 U.S. physicians, indicating strong integration and scalability for broad enterprise adoption. CardIQ Suite is deployed on-premise with GE Advantage Workstation, which might require more specific infrastructure and could limit its readiness for diverse enterprise environments.

Innovation

EchoNext

EchoNext represents a significant innovation by being the first FDA-cleared AI tool to detect hidden structural heart disease from standard ECGs, a widely available and inexpensive test. This capability allows for earlier detection of critical conditions that are often missed. CardIQ Suite's deep learning for automated calcium scoring and CCTA review is innovative within its domain, but EchoNext's application to ECGs for broad structural heart disease detection appears to be a more groundbreaking advancement in early diagnosis.

Support & Docs

Tie

Both companies are established in the healthcare technology space. GE Medical Systems SCS (CardIQ Suite) is a large, well-known entity, implying robust support and documentation, though specific details for CardIQ Suite are not provided. Pathway Labs (EchoNext) is a newer company but has secured significant funding and is partnering with a major clinical decision support platform, suggesting a commitment to support. Without specific comparative information on their support offerings or documentation, it's a tie.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	CardIQ Suite	EchoNext
Tool Name	CardIQ Suite	EchoNext
Company	GE Medical Systems SCS	Pathway Labs
Description	AI-powered cardiac CT post-processing application, offering automated calcium scoring and CCTA review for comprehensive cardiovascular disease diagnosis and treatment planning.	FDA-cleared AI tool that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension.
Categories	Cardiology AI, Radiology & Imaging AI	Cardiology AI, Clinical Decision Support & Reference, Lab & Diagnostics
Specialties	Cardiology, Radiology	Cardiology, Family Medicine, Hospital Medicine, Internal Medicine
Key Features (Examples)	Deep Learning based automated Calcium Score and labeling of coronary artery territories, Integrated workflow for seamless review of calcium scoring and CCTA data	AI-powered ECG analysis, Detection of hidden structural heart disease, Identifies heart failure risk

Videos

Demos, reviews, and walkthroughs featuring CardIQ Suite and EchoNext.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into existing cardiology workflows and EHR systems?

CardIQ Suite offers an integrated workflow for seamless review of calcium scoring and CCTA data, allowing users to transition easily between these tasks. EchoNext integrates with EHR systems through the OpenEvidence clinical decision support platform, which is used by a significant number of US clinicians, aiming to make the AI output readily available at the point of care.

What are the accuracy and sensitivity of each tool in detecting cardiac conditions?

CardIQ Suite demonstrates high accuracy in identifying coronary artery calcifications (>95%), with over 90% consistency in CACS-DRS classification and accurate labeling of coronary artery territories. EchoNext has shown high accuracy in detecting structural heart disease (SHD), with an AUROC of 85.2% in internal tests and 78-80% in external validation, outperforming cardiologists in studies by correctly identifying 77% of structural heart problems compared to 64% for cardiologists.

What is the learning curve for physicians, and what kind of support is available?

CardIQ Suite is designed with automation and workflow efficiency in mind, suggesting a focus on ease of use within its integrated CT cardiac post-processing tools. While specific details on the learning curve or support quality for CardIQ Suite are not provided, GE Medical Systems SCS typically offers support for its medical devices. EchoNext is designed to be accessible through the OpenEvidence platform, which aims to put the tool's output in front of physicians using familiar interfaces.

What clinical context or specific patient populations are these tools best suited for?

CardIQ Suite is designed for comprehensive cardiovascular disease diagnosis and treatment planning using cardiac CT, focusing on automated calcium scoring and CCTA review, including plaque visualization and quantification. EchoNext analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension, making it suitable for broad screening to identify patients who may require further imaging like echocardiograms.

What audit-trail features are available to ensure transparency and accountability in AI-assisted diagnoses?

The provided information does not explicitly detail specific audit-trail features for either CardIQ Suite or EchoNext. However, in general, robust medical AI tools are expected to maintain comprehensive logs of their analysis and outputs for accountability and review.

How do these tools support multi-site rollout and standardization across different clinical settings?

CardIQ Suite's deep learning models were developed and trained on diverse clinical datasets from a global population, spanning multiple scanner types and vendors, which may facilitate multi-site deployment and standardization. EchoNext has demonstrated consistent performance across academic and community campuses and across diverse patient demographics and clinical contexts, suggesting its suitability for multi-site rollouts and generalizability.